EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF–PD-1 antibody ivonescimab

Nina Jajcanin Jozic, Josh Bishop, Alexander R O’Shea, Gogulan Karunanithy, Catherine Lichten, Svea Cheeseman

Antibody Therapeutics · 16.07.2026

DOI: 10.1093/abt/tbag037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 16.07.2026. Verfasst von Nina Jajcanin Jozic und 5 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Refeyn Ltd..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The bispecific antibody ivonescimab targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Recent clinical trials have shown it has greater efficacy against PD-L1 positive non-small cell lung cancer than pembrolizumab (Keytruda), a frequently prescribed anti-PD-1 monoclonal antibody. Ivonescimab binds to two VEGF and two PD-1 molecules, with complex formation through higher-order structure formation (or ‘daisy chain’ binding). However, the binding stoichiometries and interaction dynamics of ivonescimab with VEGF and PD-1 have not been characterized in depth.

Methods

We used mass photometry (MP) and kinetic modeling to analyze these interactions, quantifying the complexes formed and their affinities. Dissociation constants (KD) for ivonescimab’s binding to VEGF and PD-1 were calculated from equilibrium counts and real-time measurements, respectively.

Results

VEGF drove oligomerization of ivonescimab, which bound VEGF predominantly in a 2:2 stoichiometry, with KD = 0.08 nM. Higher-order oligomeric complexes, present only at low abundance, displayed markedly weaker affinities (3.17 nM; 1.29 nM). Ternary complexes of ivonescimab with its two targets consistently presented two PD-1 antigens for each ivonescimab molecule, with a 1.66 nM KD for the binding of the first PD-1 and the slightly stronger 0.89 nM for the second PD-1 molecule.

Conclusions

MP confirmed VEGF-induced ivonescimab oligomerization and revealed that dimers, not higher-order structures, were the most stable stoichiometry. MP enables detailed analysis of antibody–antigen interactions, even for bispecific antibodies that interact with antigens with complex stoichiometries.

Förderung

  • Refeyn Ltd.

Zitieren

APA

Jozic, N. J., Bishop, J., O’Shea, A. R., Karunanithy, G., Lichten, C., & Cheeseman, S. (2026). Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF–PD-1 antibody ivonescimab. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag037

Vancouver

Jozic NJ, Bishop J, O’Shea AR, Karunanithy G, Lichten C, Cheeseman S. Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF–PD-1 antibody ivonescimab. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag037

BibTeX
@article{Jozic2026,
  author = {Jozic, Nina Jajcanin and Bishop, Josh and O’Shea, Alexander R and Karunanithy, Gogulan and Lichten, Catherine and Cheeseman, Svea},
  title = {Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF–PD-1 antibody ivonescimab},
  journal = {Antibody Therapeutics},
  year = {2026},
  doi = {10.1093/abt/tbag037}
}
Kostenlos starten →